Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
acetyl-CoA + 1-acyl-sn-glycero-3-phosphate
CoA + 2-acetyl-1-acyl-sn-glycero-3-phosphate
-
-
-
?
acetyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-acyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
acetyl-CoA + 1-hexadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphate
CoA + 2-acetyl-1-alkyl-6-phosphate
-
-
-
-
?
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
?
-
-
-
-
?
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
acetyl-CoA + 1-octadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
acetyl-CoA + 1-palmitoyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-palmitoyl-sn-glycero-3-phosphocholine
acetyl-CoA + acetyl-phosphatidylcholine
?
-
-
-
-
?
acetyl-CoA + acyl-lyso-glycero-3-phosphocholine
CoA + acetyl-acyl-glycero-3-phosphocholine
acetyl-CoA + alk-1-enyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-alk-1-enyl-glycero-3-phosphoethanolamine
acetyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 2-acetyl-alkyl-glycero-3-phosphoethanolamine
acetyl-CoA + alkyl-lyso-monomethylethanamine
?
acetyl-CoA + alkyl-lyso-N',N'-dimethylethanamine
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
acetyl-CoA + hexadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
acetyl-CoA + lyso-phosphatidylcholine
CoA + 2-acetyl-1-acylphosphatidylcholine
-
-
-
?
acetyl-CoA + lyso-phosphatidylethanolamine
CoA + 2-acetyl-1-acyl-phosphatidylethanolamine
-
-
-
?
acetyl-CoA + lyso-platelet activating factor
CoA + platelet activating factor
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
?
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
acetyl-CoA + phosphatidylcholine
?
-
-
-
-
?
butyryl-CoA + 1-alkyl-2-lyso-sn-glycero-3-phosphocholine
2-butyryl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
hexanoyl-CoA + 1-alkyl-2-lyso-sn-glycero-3-phosphocholine
2-hexanoyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
lyso-platelt activating factor + acetyl-CoA
?
-
-
-
-
?
oleoyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 1-alkyl-2-oleoyl-glycero-3-phosphoethanolamine
-
10% of the activity observed in presence of acetyl-CoA
-
?
palmitoyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-2-palmitoyl-glycero-3-phosphoethanolamine
-
5% of the activity observed in presence of acetyl-CoA
-
?
propionyl-CoA + alkyl-lyso-glycero-phosphocholine
CoA + 2-propionyl-1-alkyl-sn-glycero-3-phosphocholine
additional information
?
-
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
-
lyso-PAF, lyso-platelet-activating factor
PAF, platelet-activating factor
-
?
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
lyso-PAF, lyso-platelet-activating factor
PAF, platelet-activating factor
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
substrates are d31-16:0 LPC or d4-lyso-PAF
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
substrates are d31-16:0 LPC or d4-lyso-PAF
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-hexadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
-
40% higher activity respect to the C18 analogue
-
?
acetyl-CoA + 1-hexadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
-
final step in remodelling pathway of PAF biosynthesis
-
?
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-octadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-octadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-palmitoyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-palmitoyl-sn-glycero-3-phosphocholine
-
rate reduced to 50%
-
?
acetyl-CoA + 1-palmitoyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-palmitoyl-sn-glycero-3-phosphocholine
-
12% of the activity observed in presence of alkyl-lyso-sn-glycero-phosphocholine
-
?
acetyl-CoA + 1-palmitoyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-palmitoyl-sn-glycero-3-phosphocholine
-
rate of synthesis is 55% of the rate observed with the ether linked substrate
-
?
acetyl-CoA + acyl-lyso-glycero-3-phosphocholine
CoA + acetyl-acyl-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + acyl-lyso-glycero-3-phosphocholine
CoA + acetyl-acyl-glycero-3-phosphocholine
-
worse substrate than alkyl-lyso-glycero-3-phosphocholine
-
-
?
acetyl-CoA + alk-1-enyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-alk-1-enyl-glycero-3-phosphoethanolamine
-
-
-
?
acetyl-CoA + alk-1-enyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-alk-1-enyl-glycero-3-phosphoethanolamine
-
-
-
?
acetyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 2-acetyl-alkyl-glycero-3-phosphoethanolamine
-
-
-
?
acetyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 2-acetyl-alkyl-glycero-3-phosphoethanolamine
-
least enzyme activity
-
?
acetyl-CoA + alkyl-lyso-monomethylethanamine
?
-
-
-
-
?
acetyl-CoA + alkyl-lyso-monomethylethanamine
?
-
-
-
-
?
acetyl-CoA + alkyl-lyso-N',N'-dimethylethanamine
?
-
-
-
-
?
acetyl-CoA + alkyl-lyso-N',N'-dimethylethanamine
?
-
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
alkyl-lyso-sn-glycero-3-phosphocholine is preferred to its saturated counterpart as substrate
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
the higher the degree of methylation of the nitrogen base, the lower the enzyme activity
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
the longer the acyl-CoA length, the smaller the values of apparent Km and Vmax
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
alkyl-lyso-sn-glycero-3-phosphocholine is preferred to its saturated counterpart as substrate
-
?
acetyl-CoA + hexadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + hexadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
intracellular redox state involved in regulating synthesis of platelet-activating factor (PAF)
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
metabolic processing of platelet-activating factor (PAF) in naive and experimental allergic encephalomyelitis (EAE) mice
-
-
?
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
propionyl-CoA + alkyl-lyso-glycero-phosphocholine
CoA + 2-propionyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
propionyl-CoA + alkyl-lyso-glycero-phosphocholine
CoA + 2-propionyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
additional information
?
-
enzyme is induced by bacterial endotoxin. The enzyme catalyzes not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF
-
-
?
additional information
?
-
-
the enzyme is activated 1. by a second-order time course after stimulation with platelet-activating factor receptor, 2. by a minute-order time course after LPS stimulation in the MyD88-dependent and p38 MAPK-dependent pathway, and 3. by an hour-order time course after LPS-stimulation in the MyD88-independent and TRIF-independent pathway
-
-
?
additional information
?
-
enzyme is induced by bacterial endotoxin. The enzyme catalyzes not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF
-
-
?
additional information
?
-
LPCAT1 recognizes a wide range of acyl-CoAs as substrates, ranging from acetyl-CoA to palmitoyl-CoA
-
-
?
additional information
?
-
-
LPCAT1 recognizes a wide range of acyl-CoAs as substrates, ranging from acetyl-CoA to palmitoyl-CoA
-
-
?
additional information
?
-
LPCAT2 also possesses lysophosphatidylcholine acyltransferase, EC: 2.3.1.23, activity that catalyzes the incorporation of arachidonoyl-CoA into membrane phosphatidylcholine
-
-
?
additional information
?
-
-
LPCAT2 also possesses lysophosphatidylcholine acyltransferase, EC: 2.3.1.23, activity that catalyzes the incorporation of arachidonoyl-CoA into membrane phosphatidylcholine
-
-
?
additional information
?
-
LPCAT2 also possesses lysophosphatidylcholine acyltransferase, EC: 2.3.1.23, activity that catalyzes the incorporation of arachidonoyl-CoA into membrane phosphatidylcholine
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
-
final step in remodelling pathway of PAF biosynthesis
-
?
acetyl-CoA + lyso-platelet activating factor
CoA + platelet activating factor
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
?
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
additional information
?
-
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
-
lyso-PAF, lyso-platelet-activating factor
PAF, platelet-activating factor
-
?
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
lyso-PAF, lyso-platelet-activating factor
PAF, platelet-activating factor
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
additional information
?
-
enzyme is induced by bacterial endotoxin. The enzyme catalyzes not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF
-
-
?
additional information
?
-
-
the enzyme is activated 1. by a second-order time course after stimulation with platelet-activating factor receptor, 2. by a minute-order time course after LPS stimulation in the MyD88-dependent and p38 MAPK-dependent pathway, and 3. by an hour-order time course after LPS-stimulation in the MyD88-independent and TRIF-independent pathway
-
-
?
additional information
?
-
enzyme is induced by bacterial endotoxin. The enzyme catalyzes not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF
-
-
?
additional information
?
-
LPCAT2 also possesses lysophosphatidylcholine acyltransferase, EC: 2.3.1.23, activity that catalyzes the incorporation of arachidonoyl-CoA into membrane phosphatidylcholine
-
-
?
additional information
?
-
-
LPCAT2 also possesses lysophosphatidylcholine acyltransferase, EC: 2.3.1.23, activity that catalyzes the incorporation of arachidonoyl-CoA into membrane phosphatidylcholine
-
-
?
additional information
?
-
LPCAT2 also possesses lysophosphatidylcholine acyltransferase, EC: 2.3.1.23, activity that catalyzes the incorporation of arachidonoyl-CoA into membrane phosphatidylcholine
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-epicatechin-3-O-gallate
-
IC50: 0.072 mM
(-)-epigallocatechin
-
IC50: 0.073 mM
(-)-epigallocatechin-3-O-gallate
-
IC50: 0.046 mM
(4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diyl)bis[(2R,3R)-5,7-dihydroxy-3,4-dihydro-2H-chromene-2,3-diyl] bis(3,4,5-trihydroxybenzoate)
-
-
1,2,3,4,6-pentagalloyl-beta-D-glucose
-
IC50: 0.026 mM
1,4-diacetoxy-2-methoxy-5-methyl-3-tetradecanoyloxybenzene
-
1-acyl-sn-glycero-3-phosphate
-
competitive inhibition for 1-alkyl-sn-glycero-3-phosphate
1-methoxyphaseolidin
-
IC50: 0.048 mM
1-methoxyphaseolin
-
IC50: 0.057 mM
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
-
irreversible inhibition dependent of both 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and enzyme concentration
1-O-alkyl-sn-glycero-3-phosphocholine
-
inhibition at high concentrations due to its detergent effect
2-methoxy-1,3,4-trihydroxy-5-methylbenzene
i.e. 2-methoxy-1,3,4-trihydroxy-5-methylbenzene, isolated from Penicillium sp. strain F33
2-methoxy-5-methyl-1,3,4-triacetoxybenzene
-
2-methoxy-5-methyl-3-octadecanoyloxy-1,4-benzoquinone
-
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
3,4-dihydroxy-1,2-dimethoxy-5-methylbenzene
-
3-acetoxy-2-methoxy-5-methyl-1,4-benzoquinone
-
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
-
3-hydroxy-2-methoxy-5-methyl-1,4-benzoquinone
-
4-(1-Naphthylvinyl)pyridine
-
IC50: 0.043 mM
6,8-diprenylgenistein
-
IC50: 0.019 mM
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
i.e. Trolox, reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
ascorbic acid
-
18.3% inhibition at 1 mM
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
chiyusaponin
-
IC50: 0.2 mM
dexamethasone
-
2 mg/kg for 3 days in liver and spleen
dihydrofumigatin
i.e. 2-methoxy-1,3,4-trihydroxy-5-methylbenzene, isolated from Penicillium sp. strain F33
diisopropylfluorophosphate
ebselen
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 7.7% and 26.6% in presence of glutathione
farnesyl gallate
-
IC50: 0.066 mM
gallic acid
-
5.3% inhibition at 0.1 mM
geranyl gallate
-
IC50: 0.089 mM
glutathione
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 18.9%
H2O2
-
8% inhibition at 1 mM
licoricidin
-
IC50: 0.0077 mM
lopinavir-r
-
remaining activity in human mesangial cells: 76%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug
luteolin
-
IC50: 0.045 mM
lysophosphatidylcholine
-
inhibition at high concentrations due to its detergent effect
medroxyprogesterone
-
50 mg/kg in liver
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
MgATP2-
-
32% and 54% inhibition at 0.125 and 1 mM respectively in neuronal nuclear fraction
myricetin
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 17%
N-acetylcysteine
reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
n-dodecyl gallate
-
IC50: 0.091 mM
nordihydroguaiaretic acid
oleic acid
-
1-acyl lysolipids less inhibited than the 1-alkyl species
p-chloromercuribenzoate
-
-
palmitoyllyso-glycero-3-phosphocholine
phenylmethylsulfonyl fluoride
-
30% inhibition at 50 mM
procyanidin B-2,3,3'-di-O-gallate
-
IC50: 0.031 mM
procyanidin B-5,3,3'-di-O-gallate
-
IC50: 0.024 mM
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
pyrrolidinecarbodithioic acid
i.e. PDTC, reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
resveratrol
-
0.157 microM, results in 50% inhibition in interleukin 1beta effect on catalytic activity
serine/threonine phosphatase
-
diminishes rates of acetylation for 1-alkyl-sn-glycero-3-phosphocholine and 1-acyl-sn-glycero-3-phosphocholine
-
sodium dodecylsulfate
-
inactivation at 0.1%
tenofovir-DF
-
remaining activity in human mesangial cells: 32%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug
theaflavin
-
IC50: 0.032 mM
theaflavin-3'-O-gallate
-
IC50: 0.039 mM
theaflavin-3,3'-di-O-gallate
-
IC50: 0.028 mM
theaflavin-3-O-gallate
-
IC50: 0.058 mM
theasinensin A
-
IC50: 0.029 mM
Triton X-100
-
75 and 95% inhibition at 0.2 and 0.6 mM respectively due to detergent
tyrosol
-
0.048 microM, results in 50% inhibition in interleukin 1beta effect on catalytic activity
Urea
-
inactivation at 8 mM
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
derivative of a metabolite from Penicillium sp. F33 , strong inhibition. Compound also significantly suppresses the gene expression of lyso-PAF acetyltransferase/LPCAT2 in mouse bone marrow-derived macrophages stimulated by lipopolysaccharide
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
-
derivative of a metabolite from Penicillium sp. F33 , strong inhibition. Compound also significantly suppresses the gene expression of lyso-PAF acetyltransferase/LPCAT2 in mouse bone marrow-derived macrophages stimulated by lipopolysaccharide
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
-
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
-
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
-
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
-
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
-
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
-
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
-
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
-
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
derivative of a metabolite from Penicillium sp. F33 , strong inhibition. Compound also significantly suppresses the gene expression of lyso-PAF acetyltransferase/LPCAT2 in mouse bone marrow-derived macrophages stimulated by lipopolysaccharide; not active against lipoxygenase and cyclooxygenases
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
-
derivative of a metabolite from Penicillium sp. F33 , strong inhibition. Compound also significantly suppresses the gene expression of lyso-PAF acetyltransferase/LPCAT2 in mouse bone marrow-derived macrophages stimulated by lipopolysaccharide
acetyl-salicylic acid
-
IC50: 1.52 mM
acetyl-salicylic acid
-
weak inhibition
baicalein
-
concentration dependent inhibition, IC50: 0.105 mM
baicalein
-
IC50: 0.148 mM
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
80.4% inhibition at 0.02 mM
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
83.0% inhibition at 0.02 mM
CaCl2
-
10 mM, 46% inhibition
diisopropylfluorophosphate
-
-
diisopropylfluorophosphate
-
98% inhibition at 10 mM
EDTA
-
67.9 and 72.7% inhibition at 0.5 and 1 mM respectively
EDTA
-
1 mM, 47% inhibition
EGTA
-
-
Fe2+
-
31% inhibition at 0.01 mM
honokiol
-
IC50: 0.06 mM, reversible inhibition
indomethacin
-
IC50: 0.26 mM
indomethacin
-
weak inhibition at 1 mM
magnolol
-
IC50: 0.07 mM, reversible inhibition
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
-
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
-
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
-
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
-
MgCl2
-
-
MnCl2
-
-
nordihydroguaiaretic acid
-
concentration dependent inhibition, IC50: 0.075 mM
nordihydroguaiaretic acid
-
IC50: 0.06 mM
nordihydroguaiaretic acid
-
IC50: 0.29 mM
oleoyl-CoA
-
45-55% inhibition
oleoyl-CoA
-
16% and 36% inhibition at 0.002 and 0.01 mM respectively in neuronal nuclear fraction
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
-
90% inhibition at 0.1 mM
palmitoyl-CoA
-
-
palmitoyl-CoA
-
85% inhibition at 10 uM due to detergent effect
palmitoyllyso-glycero-3-phosphocholine
-
-
palmitoyllyso-glycero-3-phosphocholine
-
competitive inhibitor for alkyl-sn-glycero-3-phosphocholine
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
95.2% inhibition at 0.02 mM
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
95.5% inhibition at 0.02 mM
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
competitively inhibits the lyso-PAFAT activity with acetyl-CoA
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
compound competes with acetyl-CoA for the inhibition of isoform LPCAT2 lyso-PAFAT activity and suppresses platelet-activating factor biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore. The compound has low inhibitory effects on isoform LPCAT1 activity
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
83.1% inhibition at 0.02 mM
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
82.4% inhibition at 0.02 mM
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
-
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
-
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
85.4% inhibition at 0.02 mM
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
86.7% inhibition at 0.02 mM
quercetin
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 8.8%
quercetin
-
IC50: 0.08 mM
additional information
500 ml/day of low-fat milk fortified with phytosterols, linoleic and alpha linolenic acids, vitamin C, vitamin E, vitamin A, vitamin B6, vitamin B12, folic acid, magnesium and selenium has no effect on the enzyme activity in vivo
-
additional information
identification of LPCAT2-specific inhibitors in order to ameliorate platelet-activating factor-related inflammatory diseases: N-phenylmaleimide derivatives are selected from a 174000-compound library using fluorescence-based high-throughput screening followed by the evaluation of the effects on LPCAT1 and LPCAT2 activities, cell viability, and cellular platelet-activating factor production. The selected compounds have low inhibitory effects on enzyme LPCAT1 activity which is mostly expressed in the lungs where it produces platelet-activating factor, indicating that adverse effects on respiratory functions may be avoided. Structure-activity relationship, overview
-
additional information
-
inhibition of lipopolysaccharide-induced platelet activating factor production and gene expression of lysophosphatidylcholine acyltransferase (LPCAT2)/lyso-PAF acetyltransferase by synthetic fumigatin derivatives, compound stability and inhibitory potencies, synthesis and evaluation, overview. Dihydrofumigatin is isolated and identified from Penicillium sp. strain F33. In addition to the efficacy to inhibit the function of lyso/PAF acetyltransferase/LPCAT2, 3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone, 3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone, and 2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone also inhibit the expression of LPCAT2 mRNA
-
additional information
inhibition of lipopolysaccharide-induced platelet activating factor production and gene expression of lysophosphatidylcholine acyltransferase (LPCAT2)/lyso-PAF acetyltransferase by synthetic fumigatin derivatives, compound stability and inhibitory potencies, synthesis and evaluation, overview. Dihydrofumigatin is isolated and identified from Penicillium sp. strain F33. In addition to the efficacy to inhibit the function of lyso/PAF acetyltransferase/LPCAT2, 3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone, 3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone, and 2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone also inhibit the expression of LPCAT2 mRNA
-
additional information
identification of LPCAT2-specific inhibitors in order to ameliorate platelet-activating factor-related infl ammatory diseases: N-phenylmaleimide derivatives are selected from a 174000-compound library using fluorescence-based high-throughput screening followed by the evaluation of the effects on LPCAT1 and LPCAT2 activities, cell viability, and cellular platelet-activating factor production. The selected compounds have low inhibitory effects on enzyme LPCAT1 activity which is mostly expressed in the lungs where it produces platelet-activating factor, indicating that adverse effects on respiratory functions may be avoided. Structure-activity relationship, overview
-
additional information
-
identification of LPCAT2-specific inhibitors in order to ameliorate platelet-activating factor-related infl ammatory diseases: N-phenylmaleimide derivatives are selected from a 174000-compound library using fluorescence-based high-throughput screening followed by the evaluation of the effects on LPCAT1 and LPCAT2 activities, cell viability, and cellular platelet-activating factor production. The selected compounds have low inhibitory effects on enzyme LPCAT1 activity which is mostly expressed in the lungs where it produces platelet-activating factor, indicating that adverse effects on respiratory functions may be avoided. Structure-activity relationship, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.072
(-)-epicatechin-3-O-gallate
Oryctolagus cuniculus
-
IC50: 0.072 mM
0.073
(-)-epigallocatechin
Oryctolagus cuniculus
-
IC50: 0.073 mM
0.046
(-)-epigallocatechin-3-O-gallate
Oryctolagus cuniculus
-
IC50: 0.046 mM
0.029
(4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diyl)bis[(2R,3R)-5,7-dihydroxy-3,4-dihydro-2H-chromene-2,3-diyl] bis(3,4,5-trihydroxybenzoate)
Oryctolagus cuniculus
-
IC50: 0.029 mM
0.026
1,2,3,4,6-pentagalloyl-beta-D-glucose
Oryctolagus cuniculus
-
IC50: 0.026 mM
0.5
1,4-diacetoxy-2-methoxy-5-methyl-3-tetradecanoyloxybenzene
Mus musculus
pH 6.9, 37°C
0.048
1-methoxyphaseolidin
Rattus norvegicus
-
IC50: 0.048 mM
0.057
1-methoxyphaseolin
Rattus norvegicus
-
IC50: 0.057 mM
0.101
2-methoxy-1,3,4-trihydroxy-5-methylbenzene
Mus musculus
pH 6.9, 37°C
0.5
2-methoxy-5-methyl-1,3,4-triacetoxybenzene
Mus musculus
pH 6.9, 37°C
0.391
2-methoxy-5-methyl-3-octadecanoyloxy-1,4-benzoquinone
Mus musculus
pH 6.9, 37°C
0.02
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
0.0171
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.166
3,4-dihydroxy-1,2-dimethoxy-5-methylbenzene
Mus musculus
pH 6.9, 37°C
0.121
3-acetoxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
pH 6.9, 37°C
0.00758
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.02
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.00116
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.003
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
0.139
3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
pH 6.9, 37°C
0.109
3-hydroxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
pH 6.9, 37°C
0.043
4-(1-Naphthylvinyl)pyridine
Rattus norvegicus
-
IC50: 0.043 mM
0.019
6,8-diprenylgenistein
Rattus norvegicus
-
IC50: 0.019 mM
1.52
acetyl-salicylic acid
Bos taurus
-
IC50: 1.52 mM
0.00033
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.2
chiyusaponin
Rattus norvegicus
-
IC50: 0.2 mM
0.5
Decanoic acid
Mus musculus
pH 6.9, 37°C
0.419
dodecanoic acid
Mus musculus
pH 6.9, 37°C
0.066
farnesyl gallate
Oryctolagus cuniculus
-
IC50: 0.066 mM
0.089
geranyl gallate
Oryctolagus cuniculus
-
IC50: 0.089 mM
0.26
indomethacin
Bos taurus
-
IC50: 0.26 mM
0.0077
licoricidin
Rattus norvegicus
-
IC50: 0.0077 mM
0.045
luteolin
Rattus norvegicus
-
IC50: 0.045 mM
0.0116
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.02
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH 7.4, 37°C
0.183
myristic acid
Mus musculus
pH 6.9, 37°C
0.091
n-dodecyl gallate
Oryctolagus cuniculus
-
IC50: 0.091 mM
0.06 - 0.29
nordihydroguaiaretic acid
0.5
octanoic acid
Mus musculus
pH 6.9, 37°C
0.5
palmitic acid
Mus musculus
pH 6.9, 37°C
0.031
procyanidin B-2,3,3'-di-O-gallate
Oryctolagus cuniculus
-
IC50: 0.031 mM
0.024
procyanidin B-5,3,3'-di-O-gallate
Oryctolagus cuniculus
-
IC50: 0.024 mM
0.00127
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.00047
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.0133
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH 7.4, 37°C
0.02
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH 7.4, 37°C
0.0003
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.08
quercetin
Rattus norvegicus
-
IC50: 0.08 mM
0.183
tetradecanoic acid
Rattus norvegicus
-
pH 6.9, 37°C
0.032
theaflavin
Oryctolagus cuniculus
-
IC50: 0.032 mM
0.039
theaflavin-3'-O-gallate
Oryctolagus cuniculus
-
IC50: 0.039 mM
0.028
theaflavin-3,3'-di-O-gallate
Oryctolagus cuniculus
-
IC50: 0.028 mM
0.058
theaflavin-3-O-gallate
Oryctolagus cuniculus
-
IC50: 0.058 mM
0.02
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
Rattus norvegicus
-
pH 6.9, 37°C
0.02
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
Mus musculus
pH 6.9, 37°C
0.003
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
Rattus norvegicus
-
pH 6.9, 37°C
0.003
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
pH 6.9, 37°C
0.105
baicalein
Bos taurus
-
concentration dependent inhibition, IC50: 0.105 mM
0.148
baicalein
Rattus norvegicus
-
IC50: 0.148 mM
0.06
honokiol
Homo sapiens
-
IC50: 0.06 mM, reversible inhibition
0.15
honokiol
Rattus norvegicus
-
IC50: 0.15 mM
0.07
magnolol
Homo sapiens
-
IC50: 0.07 mM, reversible inhibition
0.15
magnolol
Rattus norvegicus
-
IC50: 0.15 mM
0.06
nordihydroguaiaretic acid
Homo sapiens
-
IC50: 0.06 mM
0.075
nordihydroguaiaretic acid
Bos taurus
-
concentration dependent inhibition, IC50: 0.075 mM
0.29
nordihydroguaiaretic acid
Rattus norvegicus
-
IC50: 0.29 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
two entities of lyso-PAFAT belonging to the 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) family: a constitutively expressed lyso-PAFAT, LPCAT1,and an inducible lyso-PAFAT, LPCAT2. LPCAT1 is mainly expressed in the lungs and produces PAF and dipalmitoyl-phosphatidylcholine, which is a main component of a pulmonary surfactant essential for respiration. LPCAT2 is mainly expressed in inflammatory cells and also possesses biosynthetic activities for PAF and cellular membrane phosphatidylcholine
evolution
two entities of lyso-PAFAT belonging to the 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) family: a constitutively expressed lyso-PAFAT, LPCAT1,and an inducible lyso-PAFAT, LPCAT2. LPCAT1 is mainly expressed in the lungs and produces PAF and dipalmitoyl-phosphatidylcholine, which is a main component of a pulmonary surfactant essential for respiration. LPCAT2 is mainly expressed in inflammatory cells and also possesses biosynthetic activities for PAF and cellular membrane phosphatidylcholine
metabolism
following extracellular stimulation, platelet-activating factor is rapidly biosynthesized via a remodeling pathway in inflammatory cells such as macrophages and neutrophils. In the remodeling pathway, one of the membrane phospholipids, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine is hydrolyzed by phospholipase A2 to produce free fatty acids and lyso-PAF (1-O-alkyl-2-hydroxy-sn-glycero-3-phosphocholine). Acetyl-CoA:lyso-PAF acetyltransferase (lyso-PAFAT) subsequently converts lyso-PAF to PAF, which is rapidly degraded to lyso-PAF and acetic acid by PAF acetylhydrolases, terminating its effects
metabolism
following extracellular stimulation, platelet-activating factor is rapidly biosynthesized via a remodeling pathway in inflammatory cells such as macrophages and neutrophils. In the remodeling pathway, one of the membrane phospholipids, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine is hydrolyzed by phospholipase A2 to produce free fatty acids and lyso-PAF (1-O-alkyl-2-hydroxy-sn-glycero-3-phosphocholine). Acetyl-CoA:lyso-PAF acetyltransferase (lyso-PAFAT) subsequently converts lyso-PAF to PAF, which is rapidly degraded to lyso-PAF and acetic acid by PAF acetylhydrolases, terminating its effects
metabolism
platelet-activating factor is synthesized rapidly in the remodeling pathway from its precursor membrane phospholipid, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine, involving the enzyme
metabolism
-
platelet-activating factor is synthesized rapidly in the remodeling pathway from its precursor membrane phospholipid, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine, involving the enzyme
-
physiological function
activities of phospholipase A2 and acetyl-CoA:lyso-PAF acetyltransferase (LysoPAFAT) are elevated in the spinal cord of experimental allergic encephalomyelitis (EAE) mice, an animal model for multiple sclerosis, compared with those of naive mice and correlate with disease severity
physiological function
a key metabolic enzyme of platelet-activating factor (PAF) syntesis, a potent inflammatory lipid mediator. Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid implicated in physiological as well as pathological inflammatory processes such as atherogenesis. It affects several critical points of atherogenesis including thrombosis, inflammation and oxidation. Common risk factors for atherosclerosis, namely diabetes, cigarette smoking, oxidised low-density lipoprotein (LDL) and systemic inflammation, share elevated PAF and PAF-like lipids as a common feature
physiological function
in inflammatory and allergic processes, platelet-activating factor, PAF, is biosynthesized in specific enzymatic reactions, which involve acetyl-CoA:lyso-PAF acetyltransferases
physiological function
platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid mediator. In response to extracellular stimuli, PAF is rapidly biosynthesized by lyso-PAF acetyltransferase. Under inflammatory conditions, LPCAT2, but not LPCAT1, is activated and upregulated to produce the platelet-activating factor
physiological function
platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid mediator. In response to extracellular stimuli, PAF is rapidly biosynthesized by lyso-PAF acetyltransferase. Under inflammatory conditions, LPCAT2, but not LPCAT1, is activated and upregulated to produce the platelet-activating factor
physiological function
platelet-activating factor (PAF), a potent proinflammatory lipid mediator, is synthesized rapidly in response to extracellular stimuli by the activation of acetyl-CoA:lyso-PAF acetyltransferase, lyso-PAFAT. The enzyme is rapidly phosphorylated after methylcarbamylplatelet-activating factor stimulation to enhance its enzymatic activity
physiological function
-
platelet-activating factor (PAF), a potent proinflammatory lipid mediator, is synthesized rapidly in response to extracellular stimuli by the activation of acetyl-CoA:lyso-PAF acetyltransferase, lyso-PAFAT. The enzyme is rapidly phosphorylated after methylcarbamylplatelet-activating factor stimulation to enhance its enzymatic activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Lee, T.C.; Malone, B.; Snyder, F.
A new de novo pathway for the formation of 1-alkyl-2-acetyl-sn-glycerols, precursors of platelet activating factor. Biochemical characterization of 1-alkyl-2-lyso-sn-glycero-3-P:acetyl-CoA acetyltransferase in rat spleen
J. Biol. Chem.
261
5373-5377
1986
Rattus norvegicus
brenda
Lee, T.C.; Vallari, D.S.; Snyder, F.
1-Alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase
Methods Enzymol.
209
396-401
1992
Homo sapiens
brenda
Gomez-Cambronero, J.; Velasco, S.; Sanchez-Crespo, M.; Vivanco, F.; Mato, J.M.
Partial purification and characterization of 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine: acetyl-CoA acetyltransferase from rat spleen
Biochem. J.
237
439-445
1986
Canis lupus familiaris, Rattus norvegicus
brenda
Lee, T.C.
Biosynthesis of platelet activating factor. Substrate specificity of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase in rat spleen microsomes
J. Biol. Chem.
260
10952-10955
1985
Rattus norvegicus
brenda
Wykle, R.L.; Malone, B.; Snyder, F.
Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid
J. Biol. Chem.
255
10256-10260
1980
Rattus norvegicus
brenda
Gomez-Cambronero, J.; Velasco, S.; Mato, J.M.; Sanchez-Crespo, M.
Modulation of lyso-platelet activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of cyclic AMP-dependent protein kinase
Biochim. Biophys. Acta
845
516-519
1985
Rattus norvegicus
brenda
Ninio, E.; Joly, F.; Bessou, G.
Biosynthesis of paf-acether. XI. Regulation of acetyltransferase by enzyme-substrate imbalance
Biochim. Biophys. Acta
963
288-294
1988
Homo sapiens
brenda
Gomez-Cambronero, J.; Nieto, M.L.; Mato, J.M.; Sanchez-Crespo, M.
Modulation of lyso-platelet-activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of calcium ions
Biochim. Biophys. Acta
845
511-515
1985
Rattus norvegicus
brenda
Kume, K.; Waga, I.; Shimizu, T.
Microplate chromatography assay for acetyl-CoA: lysoplatelet-activating factor acetyltransferase
Anal. Biochem.
246
118-122
1997
Sus scrofa
brenda
Roy Baker, R.; Chang, H.y.
Substrate specificities of neuronal nuclear acetyltransferases involved in the synthesis of platelet-activating factor: Differences in the use of 1-alkyl and 1-acyl lysophospholipid acceptors
Biochim. Biophys. Acta
1390
215-224
1998
Oryctolagus cuniculus
brenda
Yamazaki, R.; Sugatani, J.; Fujii, I.; Kuroyanagi, M.; Umehara, K.; Ueno, A.; Suzuki, Y.; Miwa, M.
Development of a novel method for determination of acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase activity and its application to screening for acetyltransferase inhibitors. Inhibition by magnolol and honokiol from Magnoliae cortex
Biochem. Pharmacol.
47
995-1006
1994
Homo sapiens, Rattus norvegicus
brenda
Garcia, C.; Montero, M.; Alvarez, J.; Sanchez Crespo, M.
Biosynthesis of platelet-activating factor (PAF) induced by chemotactic peptide is modulated at the lyso-PAF:acetyl-CoA acetyltransferase level by calcium transient and phosphatidic acid
J. Biol. Chem.
268
4001-4008
1993
Homo sapiens
brenda
Svetlov, S.I.; Liu, H.; Chao, W.; Olson, M.S.
Regulation of platelet-activating factor (PAF) biosynthesis via coenzyme A-independent transacylase in the macrophage cell line IC-21 stimulated with lipopolysaccharide
Biochim. Biophys. Acta
1346
120-130
1997
Mus musculus
brenda
Yanoshita, R.; Chang, H.W.; Son, K.H.; Kudo, I.; Samejina, Y.
Inhibition of lysoPAF acetyltransferase activity by flavonoids
Inflamm. Res.
45
546-549
1996
Rattus norvegicus
brenda
Nagumo, S.; Fukuju, A.; Takayama, M.; Nagai, M.; Yanoshita, R.; Samejima, Y.
Inhibition of lysoPAF acetyltransferase activity by components of licorice root
Biol. Pharm. Bull.
22
1144-1146
1999
Rattus norvegicus
brenda
Hurst, J.S.; Bazan, H.E.P.
The sensitivity of bovine corneal epithelial lyso-PAF acetyltransferase to cyclooxygenase and lipoxygenase inhibitors is independent of arachidonate metabolites
J. Ocul. Pharmacol. Ther.
13
415-426
1997
Bos taurus
brenda
Kudolo, G.B.; Yang, Y.Q.; Chen, D.B.; Jones, M.A.; Harper, M.J.K.
Differential metabolism of exogenous platelet-activating factor by glandular epithelial and stromal cells of rabbit endometrium
J. Reprod. Fertil.
105
315-324
1995
Oryctolagus cuniculus
brenda
Ihara, Y.; Frenkel, R.A.; Johnston, J.M.
Hormonal regulation of platelet-activating factor-acetyltransferase activity in rat tissues
Arch. Biochem. Biophys.
304
503-507
1993
Rattus norvegicus
brenda
Baker, R.R.; Chang, H.Y.
Alkylglycerophosphate acetyltransferase and lyso platelet activating factor acetyltransferase, two key enzymes in the synthesis of platelet activating factor, are found in neuronal nuclei isolated from cerebral cortex
Biochim. Biophys. Acta
1302
257-263
1996
Oryctolagus cuniculus
brenda
Corl, C.M.; Cao, Y.Z.; Cohen, Z.S.; Sordillo, L.M.
Oxidant stress enhances Lyso-PAF-AcT activity by modifying phospholipase D and phosphatidic acid in aortic endothelial cells
Biochem. Biophys. Res. Commun.
302
610-614
2003
Bos taurus
brenda
Nomikos, T.N.; Iatrou, C.; Demopoulos, C.A.
Acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue
Eur. J. Biochem.
270
2992-3000
2003
Homo sapiens
brenda
Sugatani, J.; Fukazawa, N.; Ujihara, K.; Yoshinari, K.; Abe, I.; Noguchi, H.; Miwa, M.
Tea polyphenols inhibit acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and platelet-activating factor-induced platelet aggregation
Int. Arch. Allergy Immunol.
134
17-28
2004
Oryctolagus cuniculus
brenda
Shindou, H.; Ishii, S.; Yamamoto, M.; Takeda, K.; Akira, S.; Shimizu, T.
Priming effect of lipopolysaccharide on acetyl-Coenzyme A:lyso-platelet-activating factor acetyltransferase is MyD88 and TRIF independent
J. Immunol.
175
1177-1183
2005
Mus musculus
brenda
Owen, J.S.; Baker, P.R.; OFlaherty, J.T.; Thomas, M.J.; Samuel, M.P.; Wooten, R.E.; Wykle, R.L.
Stress-induced platelet-activating factor synthesis in human neutrophils
Biochim. Biophys. Acta
1733
120-129
2005
Homo sapiens
brenda
Tosaki, T.; Sakamoto, H.; Kitahara, J.; Imai, H.; Nakagawa, Y.
Enhancement of acetyl-CoA: 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase activity by hydrogen peroxide
Biol. Pharm. Bull.
30
272-278
2007
Homo sapiens, Homo sapiens (Q7L5N7)
brenda
Shindou, H.; Hishikawa, D.; Nakanishi, H.; Harayama, T.; Ishii, S.; Taguchi, R.; Shimizu, T.
A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells: cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase
J. Biol. Chem.
282
6532-6539
2007
Homo sapiens (Q7L5N7), Mus musculus (Q8BYI6)
brenda
Fragopoulou, E.; Iatrou, C.; Demopoulos, C.A.
Characterization of acetyl-CoA:lyso-PAF acetyltransferase of human mesangial cells
Mediators Inflamm.
2005
263-272
2005
Homo sapiens
brenda
Kihara, Y.; Yanagida, K.; Masago, K.; Kita, Y.; Hishikawa, D.; Shindou, H.; Ishii, S.; Shimizu, T.
Platelet-activating factor production in the spinal cord of experimental allergic encephalomyelitis mice via the group IVA cytosolic phospholipase A2-Lyso-PAFAT axis
J. Immunol.
181
5008-5014
2008
Mus musculus, Mus musculus (Q8BYI6)
brenda
Tsoupras, A.B.; Chini, M.; Tsogas, N.; Fragopoulou, E.; Nomikos, T.; Lioni, A.; Mangafas, N.; Demopoulos, C.A.; Antonopoulou, S.; Lazanas, M.C.
Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?
AIDS Res. Hum. Retroviruses
24
1079-1086
2008
Homo sapiens
brenda
Egea, L.; Gimenez, R.; Lucia, D.; Modolell, I.; Badia, J.; Baldoma, L.; Aguilar, J.
Increased production of the ether-lipid platelet-activating factor in intestinal epithelial cells infected by Salmonella enteritidis
Biochim. Biophys. Acta
1781
270-276
2008
Homo sapiens
brenda
Detopoulou, P.; Nomikos, T.; Fragopoulou, E.; Antonopoulou, S.; Kotroyiannis, I.; Vassiliadou, C.; Panagiotakos, D.B.; Chrysohoou, C.; Pitsavos, C.; Stefanadis, C.
Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure
Clin. Biochem.
42
44-49
2009
Homo sapiens
brenda
Harayama, T.; Shindou, H.; Ogasawara, R.; Suwabe, A.; Shimizu, T.
Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor
J. Biol. Chem.
283
11097-11106
2008
Mus musculus (Q3TFD2), Mus musculus
brenda
Yamazaki, Y.; Yasuda, K.; Matsuyama, T.; Ishihara, T.; Higa, R.; Sawairi, T.; Yamaguchi, M.; Egi, M.; Akai, S.; Miyase, T.; Ikari, A.; Miwa, M.; Sugatani, J.
A Penicillium sp. F33 metabolite and its synthetic derivatives inhibit acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and carrageenan-induced paw edema in mice
Biochem. Pharmacol.
86
632-644
2013
Mus musculus, Mus musculus (Q8BYI6), Rattus norvegicus
brenda
Ntzouvani, A.; Nomikos, T.; Petrogianni, M.; Dede, V.; Stamatakis, G.; Manios, Y.
Effect of fortified milk on lyso-platelet-activating factor acetyltranferase and lipoprotein-associated phospholipase A2 in hypercholesterolemic adults
Eur. J. Lipid Sci. Technol.
115
142-152
2013
Homo sapiens (Q7L5N7)
-
brenda
Detopoulou, P.; Fragopoulou, E.; Nomikos, T.; Yannakoulia, M.; Stamatakis, G.; Panagiotakos, D.B.; Antonopoulou, S.
The relation of diet with PAF and its metabolic enzymes in healthy volunteers
Eur. J. Nutr.
54
25-34
2015
Homo sapiens
brenda
Morimoto, R.; Shindou, H.; Tarui, M.; Shimizu, T.
Rapid production of platelet-activating factor is induced by protein kinase Calpha-mediated phosphorylation of lysophosphatidylcholine acyltransferase 2 protein
J. Biol. Chem.
289
15566-15576
2014
Mus musculus (Q8BYI6), Mus musculus, Mus musculus C57/BL6J (Q8BYI6)
brenda
Tarui, M.; Shindou, H.; Kumagai, K.; Morimoto, R.; Harayama, T.; Hashidate, T.; Kojima, H.; Okabe, T.; Nagano, T.; Nagase, T.; Shimizu, T.
Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2
J. Lipid Res.
55
1386-1396
2014
Homo sapiens (Q7L5N7), Mus musculus (Q8BYI6), Mus musculus
brenda
Vlachogianni, I.C.; Fragopoulou, E.; Stamatakis, G.M.; Kostakis, I.K.; Antonopoulou, S.
Platelet activating factor (PAF) biosynthesis is inhibited by phenolic compounds in U-937 cells under inflammatory conditions
Prostaglandins Other Lipid Mediat.
121
176-183
2015
Homo sapiens
brenda
Gavriil, L.; Detopoulou, M.; Petsini, F.; Antonopoulou, S.; Fragopoulou, E.
Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism a randomised, double-blind and placebo-controlled trial
Br. J. Nutr.
121
982-991
2019
Homo sapiens
brenda
Argyrou, C.; Vlachogianni, I.; Stamatakis, G.; Demopoulos, C.A.; Antonopoulou, S.; Fragopoulou, E.
Postprandial effects of wine consumption on platelet activating factor metabolic enzymes
Prostaglandins Other Lipid Mediat.
130
23-29
2017
Homo sapiens
brenda